uniQure NVMEX:QUREN 29 Quick Ratio is 10.40 as of Mar. 2026, which is 15% above its 10-year median of 9.03. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, uniQure NV ranks better than 79.8% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. uniQure NV's quick ratio for the quarter that ended in Mar. 2026 was 10.40.
uniQure NV has a quick ratio of 10.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for uniQure NV's Quick Ratio or its related term are showing as below:
MEX:QUREN'
s Quick Ratio Range Over the Past 10 Years
Min: 3.64 Med: 9.03 Max: 17.09
Current: 10.4
During the past 13 years, uniQure NV's highest Quick Ratio was 17.09. The lowest was 3.64. And the median was 9.03.
MEX:QUREN's Quick Ratio is ranked better than 79.8% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs MEX:QUREN: 10.40
uniQure NV (MEX:QUREN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
uniQure NV Quick Ratio Related Terms
uniQure NV Quick Ratio Historical Data
* Premium members only.
The historical data trend for uniQure NV's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:QUREN vs NVAX, HRMY, IOVA: Quick Ratio Comparison
For the Biotechnology subindustry, uniQure NV's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Quick Ratio distribution charts can be found below:
* The bar in red indicates where uniQure NV's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
uniQure NV's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (MEX:QUREN) has a Quick Ratio of 10.40 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on uniQure NV and its competitors. This is 15% above median its historical median of 9.03. Over the past decade, uniQure NV's Quick Ratio has ranged from 3.64 to 17.09. According to the industry distribution chart, uniQure NV ranks #286 out of 1416 companies in the Biotechnology industry, placing it in the top 20.2%.
Is uniQure NV's Quick Ratio too high?
uniQure NV's current Quick Ratio of 10.40 is 15% above median its 10-year median of 9.03. Over the past 10 years, this metric has ranged from a low of 3.64 to a high of 17.09. The Biotechnology industry median Quick Ratio is 3.60. uniQure NV's value of 10.40 is 188.9% above this industry median. Based on the distribution chart, uniQure NV ranks #286 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Quick Ratio compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #286 out of 1416 companies for Quick Ratio. This places uniQure NV in the top 20% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. uniQure NV's value of 10.40 is 188.9% above this benchmark. Historically, uniQure NV's own Quick Ratio has ranged from 3.64 to 17.09 over the past decade. While the company's 10-year median is 9.03 vs. the industry median of 3.60, uniQure NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current Quick Ratio of 10.40 is 188.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Quick Ratio is 10.40, which is 15% above median its own 10-year median of 9.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current Quick Ratio is 10.40, which is 15% above median its 10-year median of 9.03 and 188.9% above the Biotechnology industry median of 3.60. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current Quick Ratio is 10.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (MEX:QUREN) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for MEX:QUREN:
Quick Ratio: 10.40 (15% above median its 10-year median of 9.03)
GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
Industry Position: 188.9% above the Biotechnology median (#286 of 1416)
No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score
Get the complete analysis for MEX:QUREN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:QUREN has been successfully added to your 
